Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Arthur Radley who wrote (33262)	12/29/2009 12:22:37 PM
From: scaram(o)uche	Read Replies (2) \| Respond to of 52153

Message 5228322 Mark Greene..... interesting to see if P.B. chimes in, but I'll just say "grain of salt"..... an academic who is often circling license and royalty revenue.

To: Arthur Radley who wrote (33262)	12/29/2009 12:24:58 PM
From: Biomaven	1 Recommendation Respond to of 52153

Here's the abstract - this antibody could be useful for diagnosis as well as treatment: PNAS Suppression of human prostate tumor growth by a unique prostate-specific monoclonal antibody F77 targeting a glycolipid marker 1. Geng Zhanga, 2. Hongtao Zhanga, 3. Qiang Wanga, 4. Priti Lala, 5. Ann M. Carrolla, 6. Margarita de la Llera-Moyab, 7. Xiaowei Xua and 8. Mark I. Greenea,1 + Author Affiliations 1. aDepartment of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA 19104-6082 2. bLipid Research Group, Children's Hospital of Philadelphia, Philadelphia, PA 19104-4318 1. Communicated by Peter C. Nowell, University of Pennsylvania School of Medicine, Philadelphia, PA, November 23, 2009 (received for review July 31, 2009) Abstract In our effort to find diagnostic markers and to develop therapeutic approaches for prostate cancer, we have identified an mAb that is capable of binding to a cell surface antigen specifically expressed on both androgen-dependent and androgen-independent prostate cancer cells. Immunohistological studies revealed that this mAb, called F77, stained 112 of 116 primary and 29 of 34 metastatic human prostate cancer specimens. Although the mAb F77 alone directly promotes prostate cancer cell death, it also mediates complement-dependent cytotoxicity and antibody-dependent cellular cytotoxicity. In addition, mAb F77 can significantly inhibit androgen-independent PC3 and Du145 tumor growth in nude mice. Antigen characterization revealed that mAb F77 recognizes a very small molecular species with glycolipid properties. F77 antigen is concentrated in the lipid-raft microdomains, which serve as platforms for the assembly of associating protein complexes. Thus, the present study indicates that mAb F77 defines a unique prostate cancer marker and shows promising potential for diagnosis and treatment of prostate cancer, especially for androgen-independent metastatic prostate cancer. * androgen-independent tumor * antibody therapy * prostate cancer lipid antigen (PCLA) * antibody-dependent cellular toxicity * lipid rafts Footnotes * 1To whom correspondence should be addressed. E-mail: greene@reo.med.upenn.edu. * Author contributions: G.Z. and M.I.G. designed research; G.Z., P.L., A.M.C., M.d.l.L.-M., and X.X. performed research; G.Z., H.Z., Q.W., and M.I.G. analyzed data; and G.Z., H.Z., Q.W., and M.I.G. wrote the paper. * The authors declare no conflict of interest. * This article contains supporting information online at www.pnas.org/cgi/content/full/0911397107/DCSupplemental.